Saturday 17 October 2026
Export MRVI’s income statement to Excel — free account
Maravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024. In the quarter to June 2026, revenue grew 8.53%, EPS grew 70.4%, free cash flow grew 127.6% and total debt fell 45.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
6.79
0.28
−3.96%
Follow MRVI
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 8.20 | 26.86 | 32.87 | 162.76 | 162.76 | — |
Piotroski F-Score |
2 | 4 | 3 | 4 | 8 | 9 | — | — | — |
P/S ratio |
2.53 | 2.90 | 3.08 | 2.04 | 6.02 | 3.99 | 34.19 | 34.19 | — |
Altman Z-Score |
0.44 | 1.17 | 1.63 | 2.67 | 4.01 | 0.88 | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 14.66 | 3.47 | 13.58 | 7.03 | 77.61 | 77.61 | — |
Altman Z″-Score (non-manufacturers) |
1.29 | 2.71 | 4.37 | 5.08 | 4.88 | 1.82 | 0.74 | 0.59 | — |
P/Operating CF |
(20.61) | (51.34) | 114.14 | 18.13 | 81.88 | 14.28 | 147.38 | 147.38 | — |
Beneish M-Score |
(3.30) | (3.93) | (4.09) | (2.32) | (0.70) | (1.58) | (2.61) | — | — |
P/B ratio |
1.26 | 1.30 | 1.13 | 1.99 | 8.82 | 7.33 | 52.41 | 52.41 | — |
Price to Tangible BV |
5.11 | 3.38 | 3.66 | 4.45 | 17.49 | 0.00 | 52.41 | 52.41 | — |
EV/Sales |
3.09 | 2.92 | 3.01 | 1.92 | 5.99 | 5.24 | 35.84 | 35.84 | — |
EV/EBITDA |
0.00 | 0.00 | 43.38 | 2.76 | 8.11 | 10.09 | 67.16 | 67.16 | — |
EV/Operating CF |
(9.97) | 101.30 | 6.89 | 3.16 | 12.99 | 9.78 | 82.02 | 82.02 | — |
EV/FCF |
(8.12) | (34.07) | 14.34 | 3.27 | 13.52 | 9.23 | 81.35 | 81.35 | — |
Quick Ratio |
5.40 | 6.34 | 7.20 | 7.07 | 7.13 | 2.20 | 1.45 | 1.05 | — |
Current Ratio |
6.60 | 7.53 | 8.00 | 7.70 | 7.89 | 2.54 | 2.05 | 1.50 | — |
Net Debt/EBITDA |
(0.69) | (0.03) | (0.94) | (0.17) | (0.03) | 2.40 | 7.34 | 7.90 | — |
Debt/Assets |
41.78% | 32.44% | 37.38% | 23.11% | 27.66% | 46.49% | 67.53% | 62.98% | 0.00% |
Debt/Equity |
0.86 | 0.57 | 0.70 | 0.58 | 0.97 | 3.82 | 2.70 | 2.30 | — |
Asset Turnover |
0.21 | 0.21 | 0.15 | 0.42 | 0.50 | 0.31 | 0.26 | 0.46 | — |
Operating CF/Net income |
0.44 | (0.05) | (1.06) | 2.43 | 2.02 | 1.98 | (5.39) | 0.04 | — |
Capex/Depreciation |
(0.21) | (0.50) | (1.27) | (0.42) | (0.39) | 0.33 | (0.66) | (0.15) | — |
Interest Coverage |
(7.98) | (4.94) | (0.69) | 28.13 | 18.33 | 3.90 | 0.80 | 0.60 | — |
| (27.53%) | (21.19%) | (14.04%) | 30.36% | 52.00% | 51.37% | (3.05%) | (3.14%) | — | |
| (14.70%) | (11.61%) | (6.31%) | 10.48% | 11.42% | 8.32% | (0.80%) | (1.66%) | — | |
ROIC |
(28.16%) | (25.31%) | (2.57%) | 44.83% | 66.07% | 14.71% | 2.94% | 2.20% | — |
Return on Tangible Assets |
(32.46%) | (26.99%) | (15.35%) | 27.86% | 26.28% | 25.45% | (3.57%) | (7.40%) | — |
Average Days of Receivables |
50.11 | 54.25 | 68.98 | 60.69 | 53.67 | 65.55 | 45.98 | 47.13 | — |
Research and Development Expense of Revenue |
9.37% | 7.42% | 5.98% | 2.08% | 1.90% | 3.27% | 2.53% | 3.63% | — |
Selling, General and Administrative Expense of Revenue |
78.13% | 62.42% | 52.39% | 14.64% | 12.52% | 33.17% | 33.78% | 33.27% | — |
Intangible Assets out of Total Assets |
0.36 | 0.35 | 0.37 | 0.22 | 0.14 | 0.32 | 0.73 | 0.82 | 0.00 |
Share Based Compensation of Revenue |
16.25% | 19.07% | 11.97% | 2.11% | 1.31% | 8.67% | 1.17% | 1.71% | — |
Graham Net Nets |
(0.22) | 0.00 | 0.00 | (0.29) | (0.13) | (0.69) | 0.01 | 0.01 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 16.08 | 12.91 | 8.57 | 0.00 | 0.00 | — |
Earnings Yield |
(27.69%) | (18.72%) | (13.35%) | 12.20% | 3.72% | 3.04% | 0.61% | 0.61% | — |
Free Cash Flow Yield |
(15.07%) | (2.95%) | 6.82% | 28.81% | 7.37% | 14.22% | 1.29% | 1.29% | — |
Revenue per Share |
1.29 | 1.88 | 2.19 | 6.71 | 6.96 | 27.45 | 0.56 | 0.49 | — |
Operating CF per Share |
(0.40) | 0.05 | 0.96 | 4.07 | 3.21 | 14.70 | 0.10 | 0.00 | — |
Capex per Share |
(0.09) | (0.22) | (0.50) | (0.13) | (0.12) | 0.88 | (0.07) | (0.01) | — |
Free Cash Flow per Share |
(0.49) | (0.16) | 0.46 | 3.94 | 3.09 | 15.58 | 0.03 | (0.01) | — |
Cash per Share |
1.50 | 2.34 | 4.36 | 4.81 | 4.80 | 22.82 | 0.10 | 0.09 | — |
Shareholders Equity per Share |
2.58 | 4.19 | 5.99 | 6.88 | 4.75 | 14.95 | 0.57 | 0.58 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.58 | 4.19 | 5.99 | 6.88 | 4.75 | 14.95 | 0.57 | 0.58 | — |
Free Cash Flow |
(70.72) | (22.49) | 60.67 | 518.89 | 354.27 | 161.28 | 6.97 | (3.80) | — |
Working Capital |
251.33 | 372.18 | 612.44 | 737.76 | 646.26 | 200.82 | 30.99 | 17.88 | — |
Capital Expenditures |
(13.15) | (29.96) | (65.55) | (17.09) | (14.30) | 9.09 | (17.15) | (3.61) | — |
Net Current Asset Value |
(101.61) | (1.89) | 2.35 | (529.17) | (632.88) | (784.35) | (372.62) | (337.86) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 2.95 | 8.63 | 12.42 | 0.00 | 0.00 | — |
Capex to Sales |
0.07 | 0.12 | 0.23 | 0.02 | 0.02 | (0.03) | 0.12 | 0.03 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 3.14 | 8.67 | 9.46 | 0.00 | 0.00 | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.41 | 0.36 | 0.32 | 0.78 | 0.78 | 0.27 | 0.27 | 0.56 | — |
Cash ROIC |
(7.76%) | (1.83%) | 3.16% | 25.13% | 21.77% | 16.43% | 1.25% | (0.74%) | — |
Accounts Receivable Turnover |
5.80 | 5.57 | 2.87 | 6.68 | 9.48 | 8.23 | 8.41 | 7.08 | — |
Accounts Payable Turnover |
20.41 | 13.30 | 17.79 | 23.89 | 17.22 | 10.18 | 12.06 | 11.05 | — |
Inventory Turnover |
3.35 | 2.97 | 3.15 | 3.57 | 3.31 | 3.35 | 4.69 | 4.34 | — |
Average Days of Payables |
7.00 | 28.93 | 26.33 | 12.94 | 21.17 | 37.44 | 40.83 | 21.65 | — |
Days of Inventory on Hand |
97.40 | 121.16 | 126.12 | 93.22 | 133.88 | 152.61 | 77.54 | 85.94 | — |
Average Receivables |
32.01 | 46.56 | 100.71 | 132.16 | 84.27 | 34.52 | 17.01 | 17.50 | — |
Average Payables |
7.43 | 11.34 | 8.36 | 7.07 | 8.16 | 7.82 | 5.54 | 5.50 | — |
Average Inventory |
45.29 | 50.74 | 47.27 | 47.35 | 42.43 | 23.75 | 14.26 | 14.00 | — |
Average Assets |
889.41 | 1,247.85 | 1,884.88 | 2,100.30 | 1,594.48 | 924.24 | 558.74 | 269.84 | — |
Average Common Equity |
474.96 | 683.55 | 847.56 | 725.30 | 350.05 | 149.69 | 146.32 | 142.50 | — |
Columns are period end dates